Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Y Lim

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
Nature Communications|December 13, 2019
The autophagy receptor p62/SQST-1 promotes proteostasis and longevity in C. elegans by inducing autophagyCaroline Kumsta, Jessica T Chang, Reina Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2006
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinomaJ Lee, W K Kang, J M Kwon, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 6, 2022
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal CancerH Jo, M-S Lee, Y-P Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2012
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinomaJ-L Lee, J-H Ahn, H Y Lim, et al.
Neoplasma|January 18, 2006
The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysisH-W Lee, J-H Choi, H-Y Lim, et al.
Cancer Chemotherapy and Pharmacology|February 8, 2011
Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patientsI G Hwang, J S Jang, J H Do, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE studyY J Kim, P Merle, R S Finn, et al.
International Journal of Oncology|September 24, 1999
Changes of telomerase and telomere lengths in paired normal and cancer tissues of breastS Y Rha, K H Park, T S Kim, et al.
American Journal of Clinical Oncology|February 1, 1996
Gastric cancer in young patients who underwent curative resection. Comparative study with older patientsJ H Choi, H C Chung, N C Yoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2013
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaA C Roy, S R Park, D Cunningham, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Nature Communications|December 13, 2019
The autophagy receptor p62/SQST-1 promotes proteostasis and longevity in C. elegans by inducing autophagyCaroline Kumsta, Jessica T Chang, Reina Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2006
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinomaJ Lee, W K Kang, J M Kwon, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 6, 2022
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal CancerH Jo, M-S Lee, Y-P Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2012
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinomaJ-L Lee, J-H Ahn, H Y Lim, et al.
Neoplasma|January 18, 2006
The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysisH-W Lee, J-H Choi, H-Y Lim, et al.
Cancer Chemotherapy and Pharmacology|February 8, 2011
Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patientsI G Hwang, J S Jang, J H Do, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE studyY J Kim, P Merle, R S Finn, et al.
International Journal of Oncology|September 24, 1999
Changes of telomerase and telomere lengths in paired normal and cancer tissues of breastS Y Rha, K H Park, T S Kim, et al.
American Journal of Clinical Oncology|February 1, 1996
Gastric cancer in young patients who underwent curative resection. Comparative study with older patientsJ H Choi, H C Chung, N C Yoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2013
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaA C Roy, S R Park, D Cunningham, et al.
Pageof 11